Evidence mapPaperPMID 42397005Full record

ReviewArchiv der Pharmazie2026

Covalent Modulation of Protein Misfolding and Aggregation Processes in the Context of Neurodegenerative Diseases.

Filippo Basagni, Elena Roggiolani, Anna Minarini, Michela Rosini

Abstract readReview
In one paragraph

Review in Archiv der Pharmazie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Filippo BasagniDepartment of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, Bologna, Italy.ORCID https://orcid.org/0000-0003-0710-4251
Elena RoggiolaniDepartment of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, Bologna, Italy.
Anna MinariniDepartment of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, Bologna, Italy.
Michela RosiniDepartment of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, Bologna, Italy.

Funding

Università di Bologna
6 · The paper itself

Abstract

Misfolded protein aggregates represent major histopathological hallmarks of neurodegenerative diseases, differing in the structural components and brain regions affected. Furthermore, the formed assemblies act as key players in developing and fostering neurotoxic processes, with distinct mechanisms depending on the stage of the amyloid cascade. Particularly, the oligomer intermediates are now considered as the main drivers of neurotoxicity, thus requiring an early antiaggregant therapeutic intervention to achieve a significant neuroprotective efficacy. Among different strategies, direct interaction at early stages preventing aggregation is quite intricate due to the considered undruggability of misfolded monomers. In this context, a covalent approach targeting specific functional nucleophilic residues within disordered proteins can offer an intriguing opportunity to overcome these weaknesses. Therefore, in this review, we outline covalent modulators of misfolding and aggregation processes reported to date, referring to the major misfolded proteins in the neurodegenerative context (i.e., β-amyloid, tau, α-synuclein, and superoxide dismutase 1) to highlight their potential both as valuable pharmacological tools or therapeutic perspectives.

Indexed as

Neurodegenerative DiseasesNeuroprotective AgentsProtein AggregatesProtein Aggregation, PathologicalProtein FoldingProteostasis Deficienciesalpha-SynucleinAmyloid beta-PeptidesAnimalsHumanstau Proteinsalpha-SynucleinAmyloid beta-PeptidesNeuroprotective AgentsProtein Aggregatestau Proteinsantiaggregating compoundscovalent inhibitorintrinsically disordered proteinsneurodegenerative diseasesproteinopathies

Identifiers

PMID42397005
PMCPMC13330560

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.